Zheng Guo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9320009/publications.pdf

Version: 2024-02-01

135 papers 3,889 citations

30 h-index 56 g-index

148 all docs $\begin{array}{c} 148 \\ \\ \text{docs citations} \end{array}$

times ranked

148

4461 citing authors

#	Article	IF	CITATIONS
1	Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes. BMC Systems Biology, 2013, 7, 101.	3.0	227
2	Identification of IncRNA-associated competing triplets reveals global patterns and prognostic markers for cancer. Nucleic Acids Research, 2015, 43, 3478-3489.	14.5	219
3	Individual-level analysis of differential expression of genes and pathways for personalized medicine. Bioinformatics, 2015, 31, 62-68.	4.1	185
4	Separate enrichment analysis of pathways for up- and downregulated genes. Journal of the Royal Society Interface, 2014, 11, 20130950.	3.4	159
5	Towards precise classification of cancers based on robust gene functional expression profiles. BMC Bioinformatics, 2005, 6, 58.	2.6	146
6	Edge-based scoring and searching method for identifying condition-responsive protein protein interaction sub-network. Bioinformatics, 2007, 23, 2121-2128.	4.1	139
7	Critical limitations of prognostic signatures based on risk scores summarized from gene expression levels: a case study for resected stage I non-small-cell lung cancer. Briefings in Bioinformatics, 2016, 17, 233-242.	6.5	126
8	Broadly predicting specific gene functions with expression similarity and taxonomy similarity. Gene, 2005, 352, 75-81.	2.2	115
9	A robust hybrid between genetic algorithm and support vector machine for extracting an optimal feature gene subset. Genomics, 2005, 85, 16-23.	2.9	112
10	Apparently low reproducibility of true differential expression discoveries in microarray studies. Bioinformatics, 2008, 24, 2057-2063.	4.1	110
11	Differential expression analysis at the individual level reveals a lncRNA prognostic signature for lung adenocarcinoma. Molecular Cancer, 2017, 16, 98.	19.2	101
12	Evaluating reproducibility of differential expression discoveries in microarray studies by considering correlated molecular changes. Bioinformatics, 2009, 25, 1662-1668.	4.1	100
13	Robust transcriptional tumor signatures applicable to both formalin-fixed paraffin-embedded and fresh-frozen samples. Oncotarget, 2017, 8, 6652-6662.	1.8	84
14	Circumvent the uncertainty in the applications of transcriptional signatures to tumor tissues sampled from different tumor sites. Oncotarget, 2017, 8, 30265-30275.	1.8	72
15	GO-function: deriving biologically relevant functions from statistically significant functions. Briefings in Bioinformatics, 2012, 13, 216-227.	6.5	71
16	Autophagyâ€related prognostic signature for breast cancer. Molecular Carcinogenesis, 2016, 55, 292-299.	2.7	68
17	Differential expression analysis for individual cancer samples based on robust within-sample relative gene expression orderings across multiple profiling platforms. Oncotarget, 2016, 7, 68909-68920.	1.8	63
18	Gaining confidence in biological interpretation of the microarray data: the functional consistence of the significant GO categories. Bioinformatics, 2008, 24, 265-271.	4.1	49

#	Article	IF	CITATIONS
19	Extracting consistent knowledge from highly inconsistent cancer gene data sources. BMC Bioinformatics, 2010, 11, 76.	2.6	46
20	Robust transcriptional signatures for low-input RNA samples based on relative expression orderings. BMC Genomics, 2017, 18, 913.	2.8	45
21	Adropin deficiency worsens HFD-induced metabolic defects. Cell Death and Disease, 2017, 8, e3008-e3008.	6.3	42
22	Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer. Oncotarget, 2015, 6, 44593-44608.	1.8	39
23	Revealing and avoiding bias in semantic similarity scores for protein pairs. BMC Bioinformatics, 2010, 11, 290.	2.6	38
24	Identifying Reproducible Molecular Biomarkers for Gastric Cancer Metastasis with the Aid of Recurrence Information. Scientific Reports, 2016, 6, 24869.	3.3	38
25	Identifying differentially expressed genes from cross-site integrated data based on relative expression orderings. International Journal of Biological Sciences, 2018, 14, 892-900.	6.4	37
26	An individualized prognostic signature and multi-omics distinction for early stage hepatocellular carcinoma patients with surgical resection. Oncotarget, 2016, 7, 24097-24110.	1.8	37
27	Effects of replacing the unreliable cDNA microarray measurements on the disease classification based on gene expression profiles and functional modules. Bioinformatics, 2006, 22, 2883-2889.	4.1	36
28	The BRCA1/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1/2. Oncotarget, 2015, 6, 2397-2406.	1.8	36
29	Quantitative or qualitative transcriptional diagnostic signatures? A case study for colorectal cancer. BMC Genomics, 2018, 19, 99.	2.8	36
30	An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups. Oncotarget, 2016, 7, 8743-8755.	1.8	36
31	An individualised signature for predicting response with concordant survival benefit for lung adenocarcinoma patients receiving platinum-based chemotherapy. British Journal of Cancer, 2016, 115, 1513-1519.	6.4	34
32	The influence of cancer tissue sampling on the identification of cancer characteristics. Scientific Reports, 2015, 5, 15474.	3.3	33
33	A qualitative signature for early diagnosis of hepatocellular carcinoma based on relative expression orderings. Liver International, 2018, 38, 1812-1819.	3.9	33
34	Multi-level reproducibility of signature hubs in human interactome for breast cancer metastasis. BMC Systems Biology, 2010, 4, 151.	3.0	30
35	Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracilâ€based adjuvant chemotherapy benefit. FASEB Journal, 2019, 33, 151-162.	0.5	29
36	Individualized analysis reveals CpG sites with methylation aberrations in almost all lung adenocarcinoma tissues. Journal of Translational Medicine, 2017, 15, 26.	4.4	28

#	Article	IF	CITATIONS
37	An individualized gene expression signature for prediction of lung adenocarcinoma metastases. Molecular Oncology, $2017, 11, 1630-1645$.	4.6	28
38	Extensive up-regulation of gene expression in cancer: the normalised use of microarray data. Molecular BioSystems, 2012, 8, 818.	2.9	27
39	A rank-based transcriptional signature for predicting relapse risk of stage II colorectal cancer identified with proper data sources. Oncotarget, 2016, 7, 19060-19071.	1.8	27
40	Globally predicting protein functions based on co-expressed protein–protein interaction networks and ontology taxonomy similarities. Gene, 2007, 391, 113-119.	2.2	26
41	Systematic analysis and prediction of longevity genes in Caenorhabditis elegans. Mechanisms of Ageing and Development, 2010, 131, 700-709.	4.6	25
42	Extensive increase of microarray signals in cancers calls for novel normalization assumptions. Computational Biology and Chemistry, 2011, 35, 126-130.	2.3	25
43	Distinct Functional Patterns of Gene Promoter Hypomethylation and Hypermethylation in Cancer Genomes. PLoS ONE, 2012, 7, e44822.	2.5	25
44	Common DNA methylation alterations of Alzheimer's disease and aging in peripheral whole blood. Oncotarget, 2016, 7, 19089-19098.	1.8	25
45	Individualized identification of disease-associated pathways with disrupted coordination of gene expression. Briefings in Bioinformatics, 2016, 17, 78-87.	6.5	24
46	Identifying clinically relevant drug resistance genes in drug-induced resistant cancer cell lines and post- chemotherapy tissues. Oncotarget, 2015, 6, 41216-41227.	1.8	24
47	A rank-based algorithm of differential expression analysis for small cell line data with statistical control. Briefings in Bioinformatics, 2019, 20, 482-491.	6.5	23
48	Prostate cancer early diagnosis: circulating microRNA pairs potentially beyond single microRNAs upon 1231 serum samples. Briefings in Bioinformatics, 2021, 22, .	6.5	23
49	Learnability-based further prediction of gene functions in Gene Ontology. Genomics, 2004, 84, 922-928.	2.9	21
50	Identification of ubiquinol cytochrome <i>c</i> reductase hinge (UQCRH) as a potential diagnostic biomarker for lung adenocarcinoma. Open Biology, 2016, 6, 150256.	3.6	21
51	Evaluating hepatocellular carcinoma cell lines for tumour samples using withinâ€sample relative expression orderings of genes. Liver International, 2017, 37, 1688-1696.	3.9	21
52	EMT-Regulome: a database for EMT-related regulatory interactions, motifs and network. Cell Death and Disease, 2017, 8, e2872-e2872.	6.3	21
53	A qualitative transcriptional signature for the early diagnosis of colorectal cancer. Cancer Science, 2019, 110, 3225-3234.	3.9	21
54	A qualitative signature for predicting pathological response to neoadjuvant chemoradiation in locally advanced rectal cancers. Radiotherapy and Oncology, 2018, 129, 149-153.	0.6	20

#	Article	IF	CITATIONS
55	Reproducibility and Concordance of Differential DNA Methylation and Gene Expression in Cancer. PLoS ONE, 2012, 7, e29686.	2.5	20
56	Network analysis of genomic alteration profiles reveals co-altered functional modules and driver genes for glioblastoma. Molecular BioSystems, 2013, 9, 467.	2.9	18
57	Systematic review regulatory principles of non-coding RNAs in cardiovascular diseases. Briefings in Bioinformatics, 2019, 20, 66-76.	6.5	18
58	Finding disease-specific coordinated functions by multi-function genes: Insight into the coordination mechanisms in diseases. Genomics, 2009, 94, 94-100.	2.9	17
59	A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation. Breast Cancer Research and Treatment, 2013, 142, 505-514.	2.5	17
60	Extracting a few functionally reproducible biomarkers to build robust subnetwork-based classifiers for the diagnosis of cancer. Gene, 2013, 526, 232-238.	2.2	17
61	Identification of molecular alterations in leukocytes from gene expression profiles of peripheral whole blood of Alzheimer's disease. Scientific Reports, 2017, 7, 14027.	3.3	17
62	Qualitative transcriptional signatures for evaluating the maturity degree of pluripotent stem cell-derived cardiomyocytes. Stem Cell Research and Therapy, 2019, 10, 113.	5.5	17
63	Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer. Breast Cancer Research and Treatment, 2013, 139, 361-369.	2.5	16
64	Identification of genes with universally upregulated or downregulated expressions in colorectal cancer. Journal of Gastroenterology and Hepatology (Australia), 2019, 34, 880-889.	2.8	16
65	GO-2D: identifying 2-dimensional cellular-localized functional modules in Gene Ontology. BMC Genomics, 2007, 8, 30.	2.8	15
66	Analysis of pathway mutation profiles highlights collaboration between cancer-associated superpathways. Human Mutation, 2011, 32, 1028-1035.	2.5	15
67	Identification of driver copy number alterations in diverse cancer types and application in drug repositioning. Molecular Oncology, 2017, 11, 1459-1474.	4.6	15
68	Genetic Interaction-Based Biomarkers Identification for Drug Resistance and Sensitivity in Cancer Cells. Molecular Therapy - Nucleic Acids, 2019, 17, 688-700.	5.1	15
69	A robust qualitative transcriptional signature for the correct pathological diagnosis of gastric cancer. Journal of Translational Medicine, 2019, 17, 63.	4.4	15
70	Comparison of different normalization assumptions for analyses of DNA methylation data from the cancer genome. Gene, 2012, 506, 36-42.	2.2	14
71	Statistically controlled identification of differentially expressed genes in one-to-one cell line comparisons of the CMAP database for drug repositioning. Journal of Translational Medicine, 2017, 15, 198.	4.4	14
72	Link synthetic lethality to drug sensitivity of cancer cells. Briefings in Bioinformatics, 2019, 20, 1295-1307.	6.5	13

#	Article	IF	CITATIONS
73	Systematic Interpretation of Comutated Genes in Large-Scale Cancer Mutation Profiles. Molecular Cancer Therapeutics, 2010, 9, 2186-2195.	4.1	12
74	Peeling Off the Hidden Genetic Heterogeneities of Cancers Based on Disease-Relevant Functional Modules. Molecular Medicine, 2006, 12, 25-33.	4.4	11
75	An Integrated Approach to Uncover Driver Genes in Breast Cancer Methylation Genomes. PLoS ONE, 2013, 8, e61214.	2.5	11
76	Identification of reproducible drug-resistance-related dysregulated genes in small-scale cancer cell line experiments. Scientific Reports, 2015, 5, 11895.	3.3	11
77	Individualized analysis of differentially expressed miRNAs with application to the identification of miRNAs deregulated commonly in lung cancer tissues. Briefings in Bioinformatics, 2018, 19, 793-802.	6.5	11
78	Locating the Genes Underlying a Simulated Complex Disease by Discriminant Analysis. Genetic Epidemiology, 2001, 21, S516-S521.	1.3	10
79	Widely predicting specific protein functions based on protein-protein interaction data and gene expression profile. Science in China Series C: Life Sciences, 2007, 50, 125-134.	1.3	10
80	Application of the rank-based method to DNA methylation for cancer diagnosis. Gene, 2015, 555, 203-207.	2.2	10
81	Identifying primary site of lung-limited Cancer of unknown primary based on relative gene expression orderings. BMC Cancer, 2019, 19, 67.	2.6	10
82	Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers. PLoS ONE, 2013, 8, e70017.	2.5	10
83	Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control. Molecular BioSystems, 2011, 7, 1158.	2.9	9
84	Reproducible Cancer Biomarker Discovery in SELDI-TOF MS Using Different Pre-Processing Algorithms. PLoS ONE, 2011, 6, e26294.	2.5	9
85	Effects and Mechanism of Bufei Yishen Formula in a Rat Chronic Obstructive Pulmonary Disease Model. Evidence-based Complementary and Alternative Medicine, 2014, 2014, 1-10.	1.2	9
86	A landscape of synthetic viable interactions in cancer. Briefings in Bioinformatics, 2018, 19, bbw142.	6.5	9
87	A qualitative transcriptional signature for the histological reclassification of lung squamous cell carcinomas and adenocarcinomas. BMC Genomics, 2019, 20, 881.	2.8	9
88	Biased Influences of Low Tumor Purity on Mutation Detection in Cancer. Frontiers in Molecular Biosciences, 2020, 7, 533196.	3.5	9
89	Revealing weak differential gene expressions and their reproducible functions associated with breast cancer metastasis. Computational Biology and Chemistry, 2012, 39, 1-5.	2.3	8
90	A qualitative transcriptional signature to reclassify estrogen receptor status of breast cancer patients. Breast Cancer Research and Treatment, 2018, 170, 271-277.	2.5	8

#	Article	IF	Citations
91	Deconvolution of the Gene Expression Profiles of Valuable Banked Blood Specimens for Studying the Prognostic Values of Altered Peripheral Immune Cell Proportions in Cancer Patients. PLoS ONE, 2014, 9, e100934.	2.5	7
92	Deciphering global signal features of high-throughput array data from cancers. Molecular BioSystems, 2014, 10, 1549-1556.	2.9	7
93	Conserved intergenic sequences revealed by CTAG-profiling in Salmonella: thermodynamic modeling for function prediction. Scientific Reports, 2017, 7, 43565.	3.3	7
94	Shared liver-like transcriptional characteristics in liver metastases and corresponding primary colorectal tumors. Journal of Cancer, 2018, 9, 1500-1505.	2.5	7
95	Transcriptomic analysis on the effects of melatonin in gastrointestinal carcinomas. BMC Gastroenterology, 2020, 20, 233.	2.0	7
96	Identification of the origin of brain metastases based on the relative methylation orderings of CpG sites. Epigenetics, 2021, 16, 908-916.	2.7	7
97	Identification of population-level differentially expressed genes in one-phenotype data. Bioinformatics, 2020, 36, 4283-4290.	4.1	7
98	Multivariate sib-pair linkage analysis of longitudinal phenotypes by three step-wise analysis approaches. BMC Genetics, 2003, 4, S68.	2.7	6
99	Identifying disease-associated pathways in one-phenotype data based on reversal gene expression orderings. Scientific Reports, 2017, 7, 1348.	3.3	6
100	A simple way to detect disease-associated cellular molecular alterations from mixed-cell blood samples. Briefings in Bioinformatics, 2018, 19, 613-621.	6.5	6
101	Identification of Common and Subtype-Specific Mutated Sub-Pathways for a Cancer. Frontiers in Genetics, 2019, 10, 1228.	2.3	6
102	A qualitative transcriptional signature for determining the grade of colorectal adenocarcinoma. Cancer Gene Therapy, 2020, 27, 680-690.	4.6	6
103	Qualitative Ras pathway signature for cetuximab therapy reveals resistant mechanism in colorectal cancer. FEBS Journal, 2020, 287, 5236-5248.	4.7	6
104	Identification of Genes Universally Differentially Expressed in Gastric Cancer. BioMed Research International, 2021, 2021, 1-9.	1.9	6
105	Qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy. Cancer Science, 2020, 111, 253-265.	3.9	6
106	An ensemble method for gene discovery based on DNA mi-croarray data. Science in China Series C: Life Sciences, 2004, 47, 396.	1.3	6
107	Functional Comparison between Genes Dysregulated in Ulcerative Colitis and Colorectal Carcinoma. PLoS ONE, 2013, 8, e71989.	2.5	6
108	Identifying CpG sites with different differential methylation frequencies in colorectal cancer tissues based on individualized differential methylation analysis. Oncotarget, 2017, 8, 47356-47364.	1.8	6

#	Article	IF	Citations
109	Discriminating cancer-related and cancer-unrelated chemoradiation-response genes for locally advanced rectal cancers. Scientific Reports, 2016, 6, 36935.	3.3	5
110	A qualitative transcriptional signature for predicting microsatellite instability status of right-sided Colon Cancer. BMC Genomics, 2019, 20, 769.	2.8	5
111	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. Journal of Cancer, 2020, 11, 883-892.	2.5	5
112	A Qualitative Transcriptional Signature for Predicting Extreme Resistance of ER-Negative Breast Cancer to Paclitaxel, Doxorubicin, and Cyclophosphamide Neoadjuvant Chemotherapy. Frontiers in Molecular Biosciences, 2020, 7, 34.	3.5	5
113	Two novel qualitative transcriptional signatures robustly applicable to nonâ€researchâ€oriented colorectal cancer samples with lowâ€quality RNA. Journal of Cellular and Molecular Medicine, 2021, 25, 3622-3633.	3.6	5
114	A Qualitative Transcriptional Signature for the Risk Assessment of Precancerous Colorectal Lesions. Frontiers in Genetics, 2020, $11,573787$.	2.3	5
115	A Qualitative Transcriptional Signature for Predicting Recurrence Risk of Stage l–III Bladder Cancer Patients After Surgical Resection. Frontiers in Oncology, 2019, 9, 629.	2.8	4
116	Identification and characterization of genes with absolute mRNA abundances changes in tumor cells with varied transcriptome sizes. BMC Genomics, 2019, 20, 134.	2.8	4
117	A qualitative transcriptional prognostic signature for patients with stage I-II pancreatic ductal adenocarcinoma. Translational Research, 2020, 219, 30-44.	5.0	4
118	Identification of a small mutation panel of coding sequences to predict the efficacy of immunotherapy for lung adenocarcinoma. Journal of Translational Medicine, 2020, 18, 25.	4.4	4
119	A qualitative transcriptional signature for predicting the biochemical recurrence risk of prostate cancer patients after radical prostatectomy. Prostate, 2020, 80, 376-387.	2.3	4
120	Identifying disease feature genes based on cellular localized gene functional modules and regulation networks. Science Bulletin, 2006, 51, 1848-1856.	1.7	3
121	Viewing cancer genes from co-evolving gene modules. Bioinformatics, 2010, 26, 919-924.	4.1	3
122	Functional modules with disease discrimination abilities for various cancers. Science China Life Sciences, 2011, 54, 189-193.	4.9	3
123	Differential degeneration of the ACTAGT sequence among Salmonella: a reflection of distinct nucleotide amelioration patterns during bacterial divergence. Scientific Reports, 2017, 7, 10985.	3.3	3
124	A Qualitative Transcriptional Signature for Predicting Recurrence Risk for High-Grade Serous Ovarian Cancer Patients Treated With Platinum-Taxane Adjuvant Chemotherapy. Frontiers in Oncology, 2019, 9, 1094.	2.8	3
125	A Qualitative Transcriptional Signature for Predicting Prognosis and Response to Bevacizumab in Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 2020, 19, 1497-1505.	4.1	3
126	A qualitative classification signature for post-surgery 5-fluorouracil-based adjuvant chemoradiotherapy in gastric cancer. Radiotherapy and Oncology, 2021, 155, 65-72.	0.6	3

ZHENG GUO

#	Article	IF	CITATIONS
127	Reversal DNA methylation patterns for cancer diagnosis. , 2014, , .		2
128	Identifying reproducible cancer-associated highly expressed genes with important functional significances using multiple datasets. Scientific Reports, 2016, 6, 36227.	3.3	2
129	A Five-Gene-Pair-Based Prognostic Signature for Predicting the Relapse Risk of Early Stage ER+ Breast Cancer. Frontiers in Genetics, 2020, 11, 566928.	2.3	2
130	Similar Source of Differential Blood mRNAs in Lung Cancer and Pulmonary Inflammatory Diseases: Calls for Improved Strategy for Identifying Cancer-Specific Biomarkers. PLoS ONE, 2014, 9, e108104.	2.5	2
131	Finding finer functions for partially characterized proteins by protein-protein interaction networks. Science Bulletin, 2007, 52, 3363-3370.	1.7	1
132	Identifying cancer genes from cancer mutation profiles by cancer functions. Science in China Series C: Life Sciences, 2008, 51, 569-574.	1.3	1
133	Evaluating FDR and stratified FDR control approaches for high-throughput biological studies. , 2012, , .		1
134	The Effects of Age, Cigarette Smoking, Sex, and Race on the Qualitative Characteristics of Lung Transcriptome. BioMed Research International, 2020, 2020, 1-7.	1.9	1
135	A Qualitative Transcriptional Signature for Predicting CpG Island Methylator Phenotype Status of the Right-Sided Colon Cancer. Frontiers in Genetics, 2020, 11, 971.	2.3	0